TWYNEO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TWYNEO (TWYNEO).
TWYNEO is a fixed-dose combination of tretinoin (retinoic acid receptor agonist) and benzoyl peroxide (antimicrobial and keratolytic). Tretinoin normalizes follicular keratinization and reduces comedone formation. Benzoyl peroxide has bactericidal activity against Propionibacterium acnes and produces mild exfoliation.
| Metabolism | Tretinoin is metabolized in the liver via oxidation by CYP2A6, CYP2B6, and CYP2E1 to metabolites including 4-hydroxy-, 4-oxo-, and 18-hydroxy-tretinoin. Benzoyl peroxide is degraded to benzoic acid, which undergoes conjugation with glycine to form hippuric acid and is excreted renally. |
| Excretion | Primarily hepatic metabolism; metabolites excreted renally (approx. 60%) and fecally (approx. 30%). |
| Half-life | Terminal half-life of tretinoin: 1-2 hours; benzoyl peroxide: <1 hour; clinical context: tretinoin undergoes rapid metabolism, benzoyl peroxide is degraded rapidly. |
| Protein binding | Tretinoin: >95% bound primarily to albumin; benzoyl peroxide: negligible binding. |
| Volume of Distribution | Tretinoin: not well-characterized topically, estimated 0.3-0.5 L/kg; benzoyl peroxide: limited systemic absorption. |
| Bioavailability | Topical: minimal systemic absorption (<2% for tretinoin; benzoyl peroxide is degraded in skin). |
| Onset of Action | Topical: noticeable reduction in acne lesions within 2-4 weeks of daily application. |
| Duration of Action | Sustained with continued use; effects persist as long as therapy is maintained; clinical improvement plateaus by 12 weeks. |
Twice daily topical application of a pea-sized amount to affected areas of the face and trunk.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment; insufficient data for severe impairment. |
| Liver impairment | No specific guidelines for hepatic impairment; use caution in severe impairment. |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | No specific adjustment; use caution due to potential increased skin sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TWYNEO (TWYNEO).
| Breastfeeding | No data on the excretion of tretinoin or benzoyl peroxide into human milk. The M/P ratio is unknown. Due to potential for adverse effects in the nursing infant, especially with tretinoin, breastfeeding is not recommended during treatment with TWYNEO. |
| Teratogenic Risk | TWYNEO (tretinoin 0.1% cream with benzoyl peroxide 3% cream) is contraindicated in pregnancy. Based on the retinoid component (tretinoin), there is a known teratogenic risk in the first trimester (major congenital malformations). Topical absorption is minimal, but systemic exposure cannot be ruled out. Avoid use in pregnancy. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Known hypersensitivity to any component of TWYNEO","Concomitant use with other topical retinoids or benzoyl peroxide products"]
| Precautions | ["Photosensitivity and use of sun protection","Local cutaneous reactions including erythema, scaling, dryness, burning, and stinging","Avoid excessive exposure to sunlight and UV light","Concomitant use of topical products with skin drying or exfoliating effects","Use in pregnancy only if clearly needed (Tretinoin is teratogenic in animals)"] |
Loading safety data…
| Fetal Monitoring | No specific fetal monitoring required as this is topical. Inadvertent use during pregnancy should prompt pregnancy testing and ultrasound to evaluate for fetal anomalies. |
| Fertility Effects | No known effects on fertility. |